SYNERGY to be Boston's "premium workhorse DES" as everolimus moves to eclipse Taxus paclitaxel line
This article was originally published in Clinica
Executive Summary
The recent CE mark approval of Boston Scientific's SYNERGY resorbable drug-eluting stent marks a significant milestone in the company's strategy to strengthen its proprietary everolimus-eluting stent (EES) offering and phase out the Abbott-licensed PROMUS stent.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.